

PEOPLE

Barry G. Pea has been named senior vice president, general counsel, and secretary of Immunex (Seattle, WA), succeeding **Scott G. Hallquist**, who will focus his efforts on the company's alliance management initiatives. Mr. Hallquist had been general counsel since 1989. Mr. Pea joined Immunex in 1996 as associate general counsel and was appointed vice president and deputy general counsel in 1998.

C. Thomas Caskey has been appointed to the board of directors of Athersys (Cleveland, OH). Dr. Caskey is currently president and COO of Cogen Biotech Ventures, and was formerly senior vice president, human genetics and vaccines discovery at Merck Research Laboratories and president of the Merck Genome Research Institute.

Celera Genomics (Rockville, MD) has announced that **Peter Chambre** has been appointed chief operating officer. Mr. Chambre was previously CEO of Bepak, a UK-based drug delivery company. Celera also named **Jason Molle** senior vice president of sales and marketing, a new position. Mr. Molle comes to the company from the Dialog Corp., most recently serving as president of North American operations.

David Chaplin has been named to the position of chief operating officer and head of R&D of Oxigene (Stockholm). Most recently, Dr. Chaplin was vice president, oncology, at Aventis Pharma.

Introgen Therapeutics (Austin, TX) has appointed **William H. Cunningham** as a member of its board of directors. Dr. Cunningham has served as chancellor and CEO of the University of Texas system since 1992. He is also a professor of marketing at the University of Texas at Austin.

Interleukin Genetics (San Antonio, TX) has named **Fenel M. Eloi** COO and CFO. He replaces **Spencer Allen**, who had been chief financial officer since 1997. Mr. Eloi had been senior vice president and CFO of LifeCell until his resignation last month.

Mark M. Foreman has been named by NeoTherapeutics (Irvine, CA) as its senior director of research. Most recently, Dr. Foreman was director of preclinical and clinical pharmacology and toxicology for SK Biopharmaceuticals, and before that, served as head of several research programs at Eli Lilly and Co.

AeroGen (Sunnyvale, CA) has announced the appointment of **Carol A. Gamble** as vice president and general counsel. Ms. Gamble was previously senior vice president and chief corporate counsel at ALZA. Before joining ALZA, she was a partner with the law firm of Heller, Ehrman, White & McAuliffe.



Cytogen (Princeton, NJ) has named **Lawrence R. Hoffman** vice president and CFO. Mr. Hoffman previously held the same positions at the Liposome Company, which was acquired in May by Elan.

Peter N. Kellogg has been appointed vice president, finance, and CFO of Biogen (Cambridge, MA). He joins the company from PepsiCo, where he was most recently senior vice president for e-commerce.

Marc J. Ostro has been named to the board of directors of NaPro BioTherapeutics (Boulder, CO). Dr. Ostro was most recently the senior managing director and head of KPMG Corporate Finance's life sciences group. He also co-founded the Liposome Company in 1981 and served as its president, vice chairman, and chief scientific officer.

Genset (Paris) has named **André G. Pernet** president and CEO, replacing **Pascal Brandys**, who has been chairman of the board and CEO since he co-founded the company in 1989. Mr. Brandys will remain on the board of directors. Dr. Pernet was formerly corporate officer and vice president, pharmaceutical products R&D of Abbott Laboratories. Genset also announced that chief biology officer and co-founder **Marc Vasseur** has announced his resignation to pursue other projects. He will also remain a company director.

Patrick Plewman, president and chief operating officer of diaDexus (Santa Clara, CA) since January, has assumed the additional responsibility of CEO. Before joining diaDexus, he was with SmithKline Beecham, where he served as director, business development—molecular diagnostics.

Eos Biotechnology (S. San Francisco, CA) has elected **Nicholas J. Pritzker** chairman of its board of directors. Mr. Pritzker is chairman and CEO of Hyatt Development and Hyatt Equities, both affiliates of Hyatt Hotel Corp., and a partner at the law firm of Pritzker and Pritzker in Chicago.